Trial · NCT01106430
Results by group92
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 92
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to First Response | Lisdexamfetamine Dimesylate | 12.0 | 95% Confidence Interval 8.0 to 16.0 | Days | |
| Time to First Response | Atomoxetine Hydrochloride | 21.0 | 95% Confidence Interval 15.0 to 23.0 | Days | |
| Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF) | Lisdexamfetamine Dimesylate | 81.7 | percentage of participants | ||
| Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF) | Atomoxetine Hydrochloride | 63.6 | percentage of participants | ||
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF | Lisdexamfetamine Dimesylate | -26.1 | Standard Error 1.16 | units on a scale | |
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF | Atomoxetine Hydrochloride | -19.7 | Standard Error 1.13 | units on a scale | |
| Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks | Lisdexamfetamine Dimesylate | -0.35 | Standard Error 0.034 | units on a scale | |
| Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks | Atomoxetine Hydrochloride | -0.27 | Standard Error 0.032 | units on a scale | |
| Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks | Lisdexamfetamine Dimesylate | 0.920 | Standard Deviation 0.0961 | units on a scale | |
| Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks | Atomoxetine Hydrochloride | 0.922 | Standard Deviation 0.0937 | units on a scale | |
| Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks | Lisdexamfetamine Dimesylate | -10.7 | Standard Deviation 9.27 | units on a scale | |
| Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks | Atomoxetine Hydrochloride | -7.9 | Standard Deviation 9.07 | units on a scale | |
| Columbia-Suicide Severity Rating Scale (C-SSRS) | Lisdexamfetamine Dimesylate | Suicidal ideation | 0 | participants | |
| Columbia-Suicide Severity Rating Scale (C-SSRS) | Atomoxetine Hydrochloride | Suicidal ideation | 0 | participants | |
| Columbia-Suicide Severity Rating Scale (C-SSRS) | Lisdexamfetamine Dimesylate | Suicidal behavior | 0 | participants | |
| Columbia-Suicide Severity Rating Scale (C-SSRS) | Atomoxetine Hydrochloride | Suicidal behavior | 0 | participants | |
| Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1 | Lisdexamfetamine Dimesylate | Weight Loss | 46 | participants | |
| Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1 | Atomoxetine Hydrochloride | Weight Loss | 19 | participants | |
| Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1 | Lisdexamfetamine Dimesylate | Reduced Duration of Sleep | 29 | participants | |
| Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1 | Atomoxetine Hydrochloride | Reduced Duration of Sleep | 16 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01106430/results